key: cord-0804412-c6ncyge7 authors: Rosemary HM Lim, Dr; Shalhoub, Reem; Sridharan, Barati Keshine title: The experiences of the community pharmacy team in supporting people with dementia and family carers with medication management during the COVID-19 pandemic. date: 2020-10-17 journal: Res Social Adm Pharm DOI: 10.1016/j.sapharm.2020.10.005 sha: 1af5be836cf6022adeff4413f972a91cdd57b4b2 doc_id: 804412 cord_uid: c6ncyge7 BACKGROUND: The novel coronavirus COVID-19 pandemic has changed the lives of people across the globe in significant and long-lasting ways. People with dementia were significantly and disproportionally affected at the height of the pandemic in England. Community pharmacies in England continued to operate during the pandemic but had to adjust the way they provided key healthcare services. The impact of these changes on the provision of medication services to people with dementia is underexplored. OBJECTIVE: To explore the experiences of the community pharmacy team in supporting people with dementia and family carers manage medications during the COVID-19 pandemic. METHODS: An interpretivist/constructivist research paradigm was used; semi-structured one-to-one telephone interviews were conducted with any member of the community pharmacy team who had been involved in providing medication services to people with dementia in England before and during the COVID-19 pandemic. Recruitment took place between July and August 2020. Interviews were audio-recorded, transcribed verbatim and analysed using thematic analysis. RESULTS: Fourteen participants were interviewed with equal numbers of qualified pharmacists and non-pharmacist staff. Participants were in their role for an average of 4.5 years. The analysis of interviews generated three themes: 1) key interactions curtailed due to COVID-19 restrictions, 2) utilising resources within and outside of the pharmacy to provide tailored services for people with dementia, and 3) the interplay between professional duty and personal values underpinned decisions to provide medication services. CONCLUSIONS: The study provided a unique and important first insights to our understanding of how the community pharmacy team in England supported people with dementia and their family carers during the COVID-19 pandemic. These insights provide opportunities for reflection by individuals, healthcare teams, healthcare organisations, policy makers and the public, in an international context, to enable long-term planning, investment and implementation of strategies beyond the current pandemic. The novel coronavirus COVID-19 pandemic has changed and is continuing to change the lives of people across the globe in significant and long-lasting ways. At the time of writing, around 35 million cases of COVID-19 infections have been reported and more than 1 million people have died because of COVID-19, worldwide 1 . It has been ten-months since the novel coronavirus was first identified in Wuhan, China and seven-months since the World Health Organisation (WHO) declared a global pandemic 2 -the world is still learning about this novel virus and the end of the pandemic is not yet in sight with a resurgence in some countries 3 . Governments and healthcare systems across the world are responding to the novel COVID-19 pandemic in different ways. In the United Kingdom (UK), the rate of infection was increasing between 5-9% per day at the time of writing 4 . The focus of the English government continues to be on reducing virus transmission. At the height of the COVID-19 pandemic in England, restrictions such as 'shielding' (not leaving their homes and minimise contact with others) clinically extremely vulnerable people, social distancing (maintaining two metres distance between individuals) and self-isolation were in place. These restrictions affected the general population and some vulnerable groups such as people with dementia were significantly and disproportionally affected 5 . Dementia was the most common pre-existing condition for COVID-19 deaths in England and Wales accounting for 25.6% of deaths 6 . More than 90% of people with dementia have at least one other health condition 7 and are at higher risk from COVID- 19. This meant that many people with dementia, of which around 61% live at home 8 and 1/3 live alone 9 , were house bound. For many people with dementia, medications are a key part of daily living. Managing medications is complex and multifaceted [10] [11] and can lead to medication errors and medication-related hospital admissions 12 . Therefore, it is important to ensure that the system of managing medications is robust and fit for purpose. During the pandemic, however, many people with dementia were not able to access medications as they would normally. Community pharmacists in the UK continued to operate during the pandemic. With around 1.6 million visits to community pharmacies per day in England alone 13 , they are one of the J o u r n a l P r e -p r o o f most easily accessible healthcare professionals providing a key health service to the population. Spaces within community pharmacies enables multiple functions and complex interactions to take place with the public, providing opportunities to support the health and wellbeing needs of the general population. However, during the pandemic, community pharmacies had to adjust the way they used such spaces and how they provided key healthcare services. The impact of these changes on the provision of medication services to vulnerable patient groups such as people with dementia was unknown. To explore the experiences of the community pharmacy team in supporting people with dementia and family carers, specific to medication management during the COVID-19 pandemic. This qualitative study is reported using COREQ 14 . The research team consisted of two undergraduate female Master of Pharmacy students (RS, BK) and a female academic pharmacist with a doctorate and experience of qualitative research methodology (RL). RS was trained by RL and conducted all the interviews. BS was trained by RL and undertook the analysis of the interviews. Purposive sampling was used to recruit participants via key contacts within RL's existing networks using email, social media (Twitter and Facebook) and word of mouth. RL emailed key contacts with the study invitation letter, participant information sheet and consent form. They then sent out information about the study via email to their own networks. The inclusion criteria were any member of the community pharmacy team who were over the age of 18 years old and had been involved in providing medication services to people with dementia in England before and during the COVID-19 pandemic. Recruitment took place in J o u r n a l P r e -p r o o f July and August 2020 until a maximum of 15 participants had been interviewed. The focus was on the 'depth/richness' of data collected rather than the breadth (e.g. existence of new information). Informed consent was given prior to interviews. An interpretivist/constructivist paradigm underpinned the design and conduct of this study 15 ; people who work in the community pharmacy have different experiences of supporting people with dementia/carers. Phenomenology as a methodology was used to explore and understand unique participants' experiences using semi-structured one-to-one interviews. Researchers actively encouraged discussions emphasising the uniqueness of participants' experiences and constructed meaning from interview data shaped by their own personal perspectives. Interviews were conducted over the telephone by a single researcher (RS) at a time that suited the participant. One-off one-to-one semi-structured interviews were conducted over the telephone. (before and during the pandemic) • On average, in a week, how many people with dementia or their carers do you meet? (before and during the pandemic) • We are interested in the types of medication services that you provide for people with dementia, living in their own home. Can you describe to me these types of services? Example before COVID-19 I am very interested to find out what life was like before the pandemic, in terms of the medication services that you provided for people with dementia. • Can you go back to before the pandemic happened and recall a specific example of a time you provided a medicine service for a person with dementia. Talk to me about the experience in as much detail as you can. Prompts: regular basis, when needed, how the service was developed, what helps, teamwork, feedback regarding service Now using this same exact service, were you able to provide this service or not since the pandemic started? • If they haven't been able to provide the service, Prompts: how do you feel about not being able to do so? What do you think needed to happen for you to be able to do it? • If they continued to be able to provide the service, Prompts: what changed from the last time you provided it? If anything? What helped you provide this service? How has the team around you contributed to it? Also, here, any feedback or way of monitoring? Generally, what changes (if any) have you incorporated into the workplace for people with dementia during the pandemic? What else could have been done differently? What do you think might/would help you do better in providing these services? If a second wave was to hit, do you think you will be prepared for it? Are there any preparations made for you to do your job safely? Is there anything else you would like to add to what we have just discussed? Interviews were analysed using inductive thematic analysis 17 . Guided extensively by RL, an experienced qualitative researcher, BK analysed the interview data. BK familiarised herself with the interview data through the transcribing of the audio-recordings, reading and rereading the interview transcripts. Using NVivo 12 18 , BK then undertook line-by-line coding of each interview transcript. Initial themes were generated and then reviewed against the interview dataset. Following further refinement of themes, BK developed a detailed analysis of each theme. The analysis process was iterative and multiple discussions were held between BK and RL at each stage of the analysis to guide the analysis process, not to achieve consensus on the interpretation of interview data. A total of 14 participants consented and took part in the interview study. Interviews took place between July and August 2020. Due to the way in which recruitment was conducted, it was not possible to ascertain the number of people whom the study invitation may have reached. Recruitment stopped when there was sufficient depth/richness to the data. Table 1 shows the demographic data of participants. Most participants were female (n=10, 71%) and half were under 30-years old. There were equal numbers of qualified pharmacists and non-pharmacist staff who took part in the study. Half of the participants worked in independent pharmacies. Pharmacies where participants worked were mostly concentrated in the South East of England (see Figure 1 ). Participants were in their current role between 4 months and 13 years (mean = 4.5 years). Interviews with participants lasted between 18 and 38 minutes (mean = 29 minutes). Medicines Services (support with taking a new medication), repeat dispensing service (dispense repeat dispensing prescriptions issued by a General Practitioner), minor ailment scheme (advice and treatment for some common illnesses) and the flu vaccination service. Most of these services are funded by the National Health Service (NHS) whilst others such as medication administration records and medication home delivery services are not. Pharmacy teams prioritised the provision of medication services that they considered to be J o u r n a l P r e -p r o o f essential during the pandemic such as compliance aids, medication administration records and medication home delivery services. Services that typically required face-to-face contact such as the Medicines Use Reviews and New Medicines Services were paused. The analysis of interviews generated three themes: 1) key interactions curtailed due to COVID-19 restrictions, 2) utilising resources within and outside of the pharmacy to provide tailored services for people with dementia, and 3) interplay between professional duty and personal values underpinned decisions to provide medication services. The This study provided a unique and possibly the first view on the experiences of the community pharmacy team in providing medication services to people with dementia and their informal carers prior to and during the COVID-19 pandemic, within an English context. Our principal findings were that key face-to-face interactions with people with dementia stopped during the COVID-19 restrictions but pharmacy teams drew extensively from internal (pharmacy/personal) and external (government) resources and negotiated J o u r n a l P r e -p r o o f professional decision-making and personal values to provide essential medication services to people with dementia. In the early stages of the COVID-19 pandemic in England, face-to-face interactions were restricted because many people with dementia were 'shielding', following government guidelines. Community pharmacy teams were able to adapt very quickly to the immediate needs of people with dementia, for example, in providing medication home delivery services, with additional funding from NHS England. Other key aspects of medication management for people with dementia, however, must not be neglected during a pandemic. Key aspects such as discussions about concerns relating to medications and regular monitoring to ensure medications are still being used appropriately are important not only to ensure medication safety but also to maintain/develop trust between the community pharmacy team and the person with dementia/informal carer. Alternative methods to communicating face-to-face such as telephone and video-consultations could be viable options [19] [20] [21] [22] to complement and not replace face-to-face communication. Empirical research on the experiences of the community pharmacy team in providing medication services to people with dementia and their carers in England during the COVID-19 pandemic is scarce. This original study provided new insight to our understanding of their experiences during a significant time-point during the pandemic. During the time of writing, there is a resurgence of COVID-19 in England and some countries worldwide. The work presented in this study will be of relevance to countries across the world during and beyond COVID-19, where community pharmacies play an important role in providing crucial medication services to people with dementia. For example, the involvement of people with dementia and carers in the design and provision of medication services, careful consideration of the use of technology to enable rather than hinder and realising the benefits of effective teamwork in better patient outcomes. An interpretivist/constructivist paradigm was used to understand the experiences of the community pharmacy team and as such, the findings were shaped by the researcher's personal experiences. A different research paradigm such as grounded theory may derive different meanings from the interview data. Although the student researchers were new to qualitative research, they were guided extensively by the research supervisor at each stage of the research process. Participants were an opportunistic sample and willing to discuss their experiences openly and in-depth. Therefore, there may be a tendency and bias towards expressing positive experiences. Participants recalled their personal experiences providing medication services to people with dementia prior to and during the pandemic. The study provided a unique and important first insights to our understanding of how the community pharmacy team in England respond to the COVID-19 pandemic, specific to the provision of medication services to people with dementia and their informal carers. The implications of the study extend beyond the current pandemic and the English context to provide opportunities for reflection by individuals, healthcare teams, healthcare organisations, policy makers and the public, to enable long-term planning, investment and implementation of strategies. COVID-19 Coronavirus Pandemic World Health Organisation (WHO) (2020a) WHO Director-General's opening remarks at the media briefing on COVID-19 -11 WHO (2020b) Coronavirus disease (COVID-19) situation reports Coronavirus (COVID-19) The R number and growth rate in the UK Alzheimer's Society (2020) Worst hit: dementia during coronavirus Deaths involving COVID-19, England and Wales: deaths occurring in Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study Dementia UK: Update People with dementia living alone: what are their needs and what kind of support are they receiving? Medicines management issues in dementia and coping strategies used by people living with dementia and family carers: a systematic review Managing medicines in the time of COVID-19: implications for community-dwelling people with dementia A systematic review of medication non-adherence in persons with dementia or cognitive impairment About community pharmacy Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups Fourth generation evaluation The Critical Incident Technique Using thematic analysis in psychology NVivo qualitative data analysis software. Version 12. QSR International Pty Ltd Telepharmacy services: present status and future perspectives: a review Remote consultations: how pharmacy teams can practise them successfully Video consultations for covid-19 Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: a China perspective National Dementia Declaration for England Is there a "Big Five" in teamwork? Teamwork behaviours and errors during neonatal resuscitation. Quality and Safety in Health Care A prospective study of paediatric cardiac surgical microsystems: assessing the relationships between non-routine events, teamwork and patient outcomes Building high reliability teams: progress and some reflections on teamwork training How effective is teamwork really? The relationship between teamwork and performance in healthcare teams: a systematic review and meta-analysis Teams, tribes and patient safety: overcoming barriers to effective teamwork in healthcare Alzheimer Europe's position on involving people with dementia in research through PPI (patient and public involvement) A strategy for human factors/ergonomics: developing the discipline and profession Safety at the sharp end: a guide to non-technical skills Safety-II in practice: developing the resilience potentials Resilient Health Care: a systematic review of conceptualisations, study methods and factors that develop resilience CRediT author statement xx: conceptualisation, methodology, writing-original draft preparation, supervision, funding acquisition. xx: investigation, writing -review and editing. xx: formal analysis, writingreview and editing We would like to thank all the community pharmacy staff members for taking time to speak with us.J o u r n a l P r e -p r o o f